Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug

International Journal of Mycobacteriology

Volumn 3, Issue 4, 2014, Pages 276-282

  Jena, Lingaraja ^a   Waghmare, Pranita ^a   Kashikar, Supriya ^b   Kumar, Satish ^a   Harinath, Bhaskar C ^a  

^a MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES   (India)

^b GeNext Genomics Pvt Ltd   (India)

Author keywords

Drug resistance; InhA; Isoniazid; KatG; Mutation

Indexed keywords

AMINE; ASPARAGINE; BACTERIAL PROTEIN; INHA PROTEIN; ISONIAZID; KATG PROTEIN; MUTANT PROTEIN; MYCOLIC ACID; NITROGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SERINE; THREONINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM MUTANT; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG ACTIVATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; HYDROGEN BOND; KATG GENE; LIPOGENESIS; MOLECULAR DOCKING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; WILD TYPE;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84918521237     PISSN: 22125531     EISSN: 2212554X     Source Type: Journal    
DOI: 10.1016/j.ijmyco.2014.08.003     Document Type: Article

References (29)

1. World Health Organization WHO Global Tuberculosis Report 2013 2013.
2. Raviglione M.C., Snider D.E., Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995, 273:220-266.
3. Shah N.S., Wright A., Bai G.H., Barrera L., Boulahbal F., Martín-Casabona N., et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 2007, 13:380-387.
4. Marrakchi H., Lanéelle G., Quémard A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology 2000, 146:289-296.
5. Middlebrook G., Cohn M.L. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953, 118:297-299.
6. Rieder H.L. Fourth-generation fluoroquinolones in tuberculosis. Lancet 2009, 373:1148-1149.
7. <>, 2014 (accessed 15.07.14). http://www.rxlist.com/isoniazid-drug/clinical-pharmacology.htm.
8. Metcalfe C., Macdonald I.K., Murphy E.J., Brown K.A., Raven E.L., Moody P.C. The tuberculosis prodrug isoniazid bound to activating peroxidases. J. Biol. Chem. 2008, 283:6193-6200.
9. Scior T., Meneses Morales I., Garcés Eisele S.J., Domeyer D., Laufer S. Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis-a review. Arch. Pharm. 2002, 335:511-525.
10. Shoeb H.A., Bowman B.U., Ottolenghi A.C., Merola A.J. Peroxidase-mediated oxidation of isoniazid. Antimicrob. Agents Chemother. 1985, 27:399-403.
11. Timmins G.S., Master S., Rusnak F., Deretic V. Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2004, 48:3006-3009.
12. Rawat R., Whitty A., Tonge P.J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:13881-13886.
13. Johnsson K., King D., Schultz P. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J. Am. Chem. Soc. 1995, 117:5009-5010.
14. Santos L.C. Review: the molecular basis of resistance in Mycobacterium tuberculosis. OJMM 2012, 2:24-36.
15. Almeida Da Silva P.E., Palomino J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 2011, 66:1417-1430.
16. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., Murray M.B. Tuberculosis drug resistance mutation database. PLoS Med. 2009, 6:e2.
17. Berman H.M., Battistuz T., Bhat T.N., Bluhm W.F., Bourne P.E., Burkhardt K., et al. The Protein Data Bank. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58:899-907.
18. Eswar N., Eramian D., Webb B., Shen M.Y., Sali A. Protein structure modeling with MODELLER. Methods Mol. Biol. 2008, 426:145-159.
19. Wang Y., Xiao J., Suzek T.O., Zhang J., Wang J., Bryant S.H. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 2009, 37:W623-W633.
20. Schüttelkopf A.W., van Aalten D.M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60:1355-1363.
21. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30:2785-2791.
22. Ramaswamy S., Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung. Dis. 1998, 79:3-29.
23. Haas W.H., Schilke K., Brand J., Amthor B., Weyer K., Fourie P.B., et al. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob. Agents Chemother. 1997, 41:1601-1603.
24. Wiederstein M., Sippl M.J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007, 35:W407-W410.
25. Wallner B., Elofsson A. Can correct protein models be identified?. Protein Sci. 2003, 12:1073-1086.
26. Mathiesen L., Malterud K.E., Sund R.B. Hydrogen bond formation as basis for radical scavenging activity: a structure-activity study of C-methylated dihydrochalcones from Myrica gale and structurally related acetophenones. Free Radic. Biol. Med. 1997, 22:307-311.
27. Nguyen M., Quemard A., Broussy S., Bernadou J., Meunier B. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2002, 46:2137-2144.
28. Rozwarski D.A., Grant G.A., Barton D.H., Jacobs W.R., Sacchettini J.C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998, 279:98-102.
29. Rozwarski D.A., Vilchèze C., Sugantino M., Bittman R., Sacchettini J.C. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J. Biol. Chem. 1999, 274:15582-15589.